All In Biotech

Drug Trial Radar · NCT06947226

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

A Phase Ib/ll Clinical Study of Safety and Efficacy of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

Apr 2026

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.

Conditions

  • Solid Tumors

Interventions

  • 9MW2821Drug

    Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

  • Other anti-cancer therapyDrug

    Subjects will receive other anticancer therapy as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AE/SAE (phase Ib)Time frame: Up to approximately 24 months
  2. Objective Response Rate, ORR (phase II)Time frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.